Status:
COMPLETED
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Lead Sponsor:
Johannes Gutenberg University Mainz
Collaborating Sponsors:
Ministry of Health, Rhineland-Palatinate, Germany
Ministry of Economics, Rhineland-Palatinate, Germany
Conditions:
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine. Increasing life-exp...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age ≥ 18 years of age at study inclusion
- Written informed consent by patient or legal guardian, if appointed
- Cohort A: Pretreatment with oral anticoagulation therapy with vitamin K antagonists (VKA) for at least 4 months in regular medical care including patients with self-management of oral anticoagulation therapy
- Cohort B: Indication for oral anticoagulation therapy with VKA for at least 3 months (both drug-naive and -experienced patients) at enrolment including patients with self-management of oral anticoagulation therapy.
- Exclusion Criteria
- Contraindication to VKA treatment, e.g. pregnancy or known hypersensitivity
- Participation in other clinical trial
Exclusion
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
2318 Patients enrolled
Trial Details
Trial ID
NCT01809015
Start Date
January 1 2011
End Date
March 1 2018
Last Update
August 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center of the Johannes Gutenberg University Mainz
Mainz, Rhineland-Palatinate, Germany, 55131